Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Current Assets (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Current Assets data on record, last reported at $296.3 million in Q4 2025.

  • For Q4 2025, Current Assets fell 30.97% year-over-year to $296.3 million; the TTM value through Dec 2025 reached $296.3 million, down 30.97%, while the annual FY2025 figure was $296.3 million, 30.97% down from the prior year.
  • Current Assets reached $296.3 million in Q4 2025 per MRVI's latest filing, down from $325.9 million in the prior quarter.
  • Across five years, Current Assets topped out at $847.9 million in Q4 2022 and bottomed at $296.3 million in Q4 2025.
  • Average Current Assets over 5 years is $610.5 million, with a median of $685.4 million recorded in 2024.
  • Peak YoY movement for Current Assets: surged 123.17% in 2021, then plummeted 52.01% in 2025.
  • A 5-year view of Current Assets shows it stood at $740.0 million in 2021, then rose by 14.58% to $847.9 million in 2022, then fell by 17.45% to $699.9 million in 2023, then plummeted by 38.69% to $429.1 million in 2024, then plummeted by 30.97% to $296.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $296.3 million in Q4 2025, $325.9 million in Q3 2025, and $359.8 million in Q2 2025.